Protein & Cell says it published the human germline editing paper as a "sounding of an alarm."
The gene editing company priced its initial public offering of 5.5 million American Depositary Shares with expectations of going public on the Nasdaq.
The African turquoise killifish, which lives only four to six months, has been transformed into a platform for genetic research with the help of CRISPR/Cas9 genome editing.
The partners are the Wellcome Trust Sanger Institute, The Innovative Genomics Initiative, Thermo Fisher Scientific, and the Broad and Whitehead Institutes.
Novartis looks toward employing the CRISPR genome-editing tool to develop new therapeutics and as a research tool.
The arrangement covers Cellectis' TALEN technology and Two Blades' TAL effector code technology.
Technology Review examines who owns the CRISPR/Cas9 gene editing approach.
The licenses provide non-exclusive access to the IP for research applications.
NEW YORK (GenomeWeb) – Researchers from New York University Langone School of Medicine have developed a synthetic biology method to linearize circular DNA molecules in vivo.
NEW YORK (GenomeWeb) – Clontech Laboratories today announced a non-exclusive licensing deal with the Broad Institute for its CRISPR-Cas9 technology.
Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.
The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.
One gene regulates hundreds of others to influence facial development, according to New Scientist.
In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.